Jeevan Scienti.

Why is Jeevan Scientific Technology Ltd falling/rising?

As of 11-Aug, Jeevan Scientific Technology Ltd's stock price is rising to Rs 80.39, reflecting a 2.3% increase. This growth is driven by strong performance metrics, positive trading activity, and increased investor participation, with the stock outperforming the Sensex significantly over various time frames.

As of 11-Aug, Jeevan Scientific Technology Ltd's stock price is rising, currently at Rs 80.39, reflecting a change of Rs 1.81 or 2.3% increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 4.35% compared to the Sensex's decline of 0.35%. Additionally, the stock has shown strong performance over the past month, with a 13.42% increase, while the Sensex has only risen by 0.75%. Year-to-date, Jeevan Scientific Technology Ltd has achieved a remarkable 24.71% gain, contrasting sharply with the Sensex's decline of 8.29%.<BR><BR>Today's trading also indicates positive momentum, as the stock reached an intraday high of Rs 80.83, marking a 2.86% increase. Furthermore, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a bullish signal. The rising investor participation is evident, with a delivery volume of 21.09k on August 10, which has increased by 23.43% compared to the 5-day average. This suggests growing interest and confidence among investors in the stock, contributing to its rising price. Overall, the combination of strong performance metrics, positive trading activity, and increased investor participation supports the stock's upward trend.

Which are the latest news on Jeevan Scienti.?

When is the next results date for Jeevan Scientific Technology Ltd?

The next results date for Jeevan Scientific Technology Ltd is 13 August 2026.

The next results date for Jeevan Scientific Technology Ltd is scheduled for 13 August 2026.

How big is Jeevan Scienti.?

As of 10th June, Jeevan Scientific Technology Ltd has a market capitalization of 159.00 Cr and reported net sales of 61.54 Cr with a net loss of 0.16 Cr over the latest four quarters. Shareholder's funds are 49.94 Cr, and total assets amount to 77.37 Cr.

As of 10th June, Jeevan Scientific Technology Ltd has a market capitalization of 159.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 61.54 Cr. However, it experienced a net loss of 0.16 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's funds are recorded at 49.94 Cr, while total assets amount to 77.37 Cr.

Who are in the management team of Jeevan Scienti.?

The management team of Jeevan Scienti includes K Krishna Kishore (Vice Chairman & Managing Director), T Ravi Babu, G Bhanu Prakash (Independent Director), Koteswara Rao SSR (Chairman & Independent Director), K Rama Krishna Prasad, Snigdha Mothukuri (Executive Director & CEO), K. Jeevan Krishna, Sharvari Swapnil Shinde (Company Secretary), and Nageswar Rao Yarllagadda. They are responsible for the company's strategic direction and operations.

The management team of Jeevan Scienti includes the following individuals:<BR><BR>1. K Krishna Kishore - Vice Chairman & Managing Director<BR>2. T Ravi Babu - Director<BR>3. G Bhanu Prakash - Independent Director<BR>4. Koteswara Rao SSR - Chairman & Independent Director<BR>5. K Rama Krishna Prasad - Director<BR>6. Snigdha Mothukuri - Executive Director & CEO<BR>7. K. Jeevan Krishna - Director<BR>8. Sharvari Swapnil Shinde - Company Secretary<BR>9. Nageswar Rao Yarllagadda - Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations. If you have any more questions about the company or its management, feel free to ask!

Who are the peers of the Jeevan Scienti.?

Peers of Jeevan Scienti. include Prevest Denpro, Take Solutions, Nureca, Star Imaging, Bilcare, Aspira Pathlab, QMS Medical, and Aakaar Medical. Jeevan Scienti. has average management risk and growth, with a 1-year return of 95.63%, lower than Take Solutions' 239.04% but higher than Bilcare's -24.68%.

Peers: The peers of Jeevan Scienti. are Prevest Denpro, Take Solutions, Nureca, Star Imaging, Bilcare, Aspira Pathlab, QMS Medical, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prevest Denpro and Aakaar Medical, while Average management risk is found at QMS Medical and Jeevan Scienti. Below Average management risk is noted at Take Solutions, Nureca, Bilcare, Aspira Pathlab, and the rest. Growth is Good at Aakaar Medical, while Average growth is seen at Jeevan Scienti. and Aspira Pathlab, and Below Average growth is reported at Prevest Denpro, Take Solutions, Nureca, Star Imaging, Bilcare, and the rest. Capital Structure is Excellent at Prevest Denpro and Star Imaging, Average at Jeevan Scienti. and QMS Medical, and Below Average at Take Solutions, Nureca, Bilcare, Aspira Pathlab, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Take Solutions at 239.04%, while Bilcare has the lowest at -24.68%. Jeevan Scienti.'s 1-year return of 95.63% is significantly higher than Bilcare's but lower than Take Solutions'. Additionally, peers with negative six-month returns include Prevest Denpro, Nureca, Bilcare, and Earkart.

What does Jeevan Scienti. do?

Jeevan Scientific Technology Ltd is an independent clinical contract research organization providing technology-driven clinical research solutions. As of March 2026, it reported net sales of 21 Cr and a net profit of 2 Cr, with a market cap of INR 159 Cr.

Overview: <BR>Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization operating in the Healthcare Services industry within the Micro Cap market segment, providing reliable and technology-driven clinical research solutions.<BR><BR>History: <BR>The company was incorporated on 2nd February 1999, previously known as Jeevan Softech Limited. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 21 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 159 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.16 <BR>Return on Equity: -0.22% <BR>Price to Book: 2.15<BR><BR>Contact Details: <BR>Address: Plot 1 & 2 Sai Krupa Enclave, Manikonda Jagir Nr Lanco Hills Hyderabad Telangana : 500008 <BR>Tel: 91-40-67364700 <BR>Email: info@jeevanscientific.com <BR>Website: http://www.jeevanscientific.com

Should I buy, sell or hold Jeevan Scientific Technology Ltd?

Are Jeevan Scientific Technology Ltd latest results good or bad?

Jeevan Scientific Technology Ltd's latest results show strong revenue growth with a net profit increase of 13.38% and a 111.63% rise in net sales, but profitability remains a concern due to a significant drop in operating margins and negative return metrics, leading to investor skepticism reflected in a 1.30% stock decline. Overall, while revenue is improving, the company faces challenges in achieving sustainable profitability.

Jeevan Scientific Technology Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹1.61 crores for Q4 FY26, which is a 13.38% increase from the previous quarter, and net sales reached ₹21.29 crores, reflecting a remarkable 111.63% year-on-year growth. This marks the highest quarterly revenue in the company's recent history, suggesting improved client traction in its clinical research and data management services.<BR><BR>However, despite these positive revenue figures, the company continues to face significant challenges. The operating margin has compressed from 27.43% to 20.24% quarter-on-quarter, indicating rising cost pressures. Additionally, the company's profitability metrics remain concerning, with a negative return on equity (ROE) of -9.28% and a return on capital employed (ROCE) of -6.57% in the latest quarter. This suggests that while revenue is growing, the company is struggling to translate that growth into sustainable profitability.<BR><BR>The stock's decline of 1.30% to ₹83.26 following the results announcement reflects investor skepticism regarding the sustainability of this turnaround, especially given the company's history of operational volatility and loss-making status on a trailing twelve-month basis. Overall, while there are signs of improvement in revenue, the underlying profitability challenges raise questions about the company's long-term viability.

How has been the historical performance of Jeevan Scienti.?

Jeevan Scienti's historical performance shows fluctuating financial metrics, with net sales rising to 46.84 Cr in Mar'25 from 36.18 Cr in Mar'23, but still below the peak of 67.79 Cr in Mar'22. Operating profit improved to 8.06 Cr in Mar'25, while profit before and after tax returned to positive figures, indicating a recovery despite increased total assets and liabilities.

Answer:<BR>The historical performance of Jeevan Scienti shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jeevan Scienti's net sales have seen a rise from 36.18 Cr in Mar'23 to 46.84 Cr in Mar'25, although they peaked at 67.79 Cr in Mar'22. The total operating income followed a similar pattern, increasing to 46.84 Cr in Mar'25 from 39.65 Cr in Mar'24, yet it remains below the 67.79 Cr recorded in Mar'22. The company's operating profit (PBDIT) has improved significantly, reaching 8.06 Cr in Mar'25 from 5.29 Cr in Mar'24, but it is still a decline from the 22.67 Cr in Mar'22. Profit before tax has shown a recovery to 0.05 Cr in Mar'25 from a loss of 1.60 Cr in Mar'24, while profit after tax also returned to a positive figure of 0.06 Cr in Mar'25, compared to a loss of 1.33 Cr in the previous year. The total assets of the company increased to 77.37 Cr in Mar'25 from 66.95 Cr in Mar'24, reflecting a growth trend, while total liabilities also rose to 77.37 Cr from 66.95 Cr, indicating a proportional increase in debt levels. Cash flow from operating activities improved to 10.00 Cr in Mar'25 from 2.00 Cr in Mar'24, showcasing a positive shift in cash generation capabilities.

Is Jeevan Scienti. overvalued or undervalued?

As of August 18, 2025, Jeevan Scienti. is considered overvalued and risky due to a negative PE ratio of -15.40, an EV to EBITDA ratio of 34.18, a low ROCE of 1.66%, and underperformance compared to peers and the Sensex.

As of 18 August 2025, the valuation grade for Jeevan Scienti. has moved from very attractive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, particularly with a PE ratio of -15.40 and an EV to EBITDA ratio of 34.18, which are concerning indicators of financial health. Additionally, the ROCE stands at a mere 1.66%, further underscoring the company's struggles to generate returns.<BR><BR>When comparing Jeevan Scienti. to its peers, it stands out negatively. For instance, Sun Pharma. has a PE ratio of 34.14 and an EV to EBITDA of 23.11, while Cipla shows a PE of 23.52 and an EV to EBITDA of 16.57, both of which are significantly more favorable. The company's stock has also underperformed relative to the Sensex, with a year-to-date return of -20.48% compared to the Sensex's 4.01%. Overall, Jeevan Scienti. is assessed as overvalued given its poor financial ratios and relative performance against industry peers.

Who are the top shareholders of the Jeevan Scienti.?

The top shareholders of Jeevan Scienti are Krishna Kishore Kuchipudi with 12.22% and Durisala Desaiah with 5.24%. Individual investors hold a combined 42.99%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Jeevan Scienti include Krishna Kishore Kuchipudi, who holds the highest promoter stake at 12.22%. The highest public shareholder is Durisala Desaiah, with a holding of 5.24%. Additionally, individual investors collectively hold 42.99% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Jeevan Scienti.?

As of June 2, 2025, Jeevan Scienti's technical trend has shifted to a moderate bearish stance, supported by bearish signals from MACD, Bollinger Bands, moving averages, and KST indicators across multiple time frames.

As of 2 June 2025, the technical trend for Jeevan Scienti has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages are also bearish, and both the weekly and monthly KST are bearish, further supporting the negative trend. The Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. Overall, the combination of these indicators suggests a bearish sentiment in the market for Jeevan Scienti.

Has Jeevan Scienti. declared dividend?

Jeevan Scientific Technology Ltd has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 21, 2022. Despite the dividend declaration, the company has experienced significant negative total returns over shorter periods, though it saw a positive return of 122.3% over the past five years.

Jeevan Scientific Technology Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 21 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -23.55%, with a dividend return of 0%, resulting in a total return of -23.55%.<BR><BR>For the 1-year period, the price return was -17.17%, with a dividend return of 0%, leading to a total return of -17.17%.<BR><BR>Over the 2-year period, the price return was -7.49%, and the dividend return was 0%, resulting in a total return of -7.49%.<BR><BR>In the 3-year period, the price return was -36.89%, with a dividend return of 2.09%, culminating in a total return of -34.8%.<BR><BR>For the 4-year period, the price return was -55.82%, and the dividend return was 1.95%, leading to a total return of -53.87%.<BR><BR>Over the 5-year period, the price return was 113.4%, with a dividend return of 8.90%, resulting in a total return of 122.3%.<BR><BR>Overall, while Jeevan Scientific Technology Ltd has declared a dividend, the total returns over various periods show significant volatility, with negative returns dominating in shorter time frames, though there was a substantial positive return over the 5-year period.